We always think of our customers with an open mind
Press Release
NTL Signs MOU with Vietnamese ‘Dong Nam Pharma’…“To Contribute to Vietnamese Women's Health Promotion”
Author
엔티엘헬스케어
Date
2023-05-31 11:54
Views
281
NTL Signs MOU with Vietnamese ‘Dong Nam Pharma’… “To Contribute to Vietnamese Women's Health Promotion”
Image - (From left) Dale Edward Washington, Attorney of Vietnamese Dong Nam Pharma; Le Thi Giau, Chairwoman of Vietnamese Dong Nam Pharma; Hyeon-su Shin, Chairman of NTL Medical Institute; and Tae-hee Kim, CEO of NTL Healthcare.
The NTL Group (Chairman Hyeon-su Shin, CEO Tae-hee Kim) has laid the groundwork for entering the Vietnamese market.
NTL Group announced on the 8th that it has signed a memorandum of understanding (MOU) with Dong Nam Pharma (Chairwoman LE THI GIAU) for 'medical cooperation between the two sides for Vietnamese women's health promotion.'
On the 3rd, the signing ceremony was held at the headquarters of NTL Healthcare Co., Ltd. in Seongnam, Gyeonggi Province, attended by Hyeon-su Shin (Chairman of the NTL Medical Institute), Tae-hee Kim (CEO of NTL Healthcare), Le Thi Giau (Chairwoman of Dong Nam Pharma), and Dale Edward Washington (Attorney).
The agreement is aimed at improving the cervical cancer screening rate across Vietnam and promoting medical cooperation for the health promotion of Vietnamese women by supplying CerviCARE® AI, an economic and high-accuracy artificial intelligence (AI) screening system for cervical cancer, to Vietnam.
CerviCARE® AI is an AI screening system that can diagnose cervical cancer test results on site within 5 seconds (1). Based on big data accumulated by NTL for 27 years, it shows a high sensitivity. In December of last year, it was approved for a Class 3 AI software for gynecologic medical treatment from the Ministry of Food and Drug Safety.
NTL plans to supply the CerviCARE® AI system to all of Vietnam through Dong Nam Pharma. Following the management philosophy of Chairwoman Le Thi Giau, Dong Nam Pharma plans to launch a free AI screening program for cervical cancer targeting underprivileged women who have difficulty receiving medical services in 10 major cities out of 63 cities in Vietnam. It is also working on a long-term plan to apply the system to over 40,000 clinics and public health centers. In addition, academic research and seminars are planned to be held in Vietnam.
Hyeon-su Shin, Chairman of NTL Medical Institute, stated, "According to the WHO, the cervical cancer screening rate in Vietnam is only one-third that of Korea. It is the biggest cause of the high mortality rate of cervical cancer, and through this agreement, NTL will also provide fully support to improve the medical environment in Vietnam."
NTL received medical device approval from the Thailand Food and Drug Administration (TFDA) in April to expand into overseas markets, and is currently in the process of approval from the Brazilian Health Regulatory Agency (ANVISA) for registration.
Tae-hee Kim, CEO of NTL Healthcare, said, "CerviCARE® AI is a system that allows women to receive safe and convenient cervical cancer screening, regardless of borders and regions, even in areas where medical infrastructure is underdeveloped. Starting with Vietnam, we plan to expand the supply of CerviCARE® AI services to Southeast Asian countries such as Laos, Cambodia, Myanmar, and Indonesia."
Meanwhile, NTL is a company that introduced cervical magnification imaging and reading system in Korea in 1996, and its cervical cancer remote diagnosis system, developed with proprietary technology, has been verified in Korea and is currently expanding to various countries around the world.
Ref: 1) Test Report, Standard Bank, 2023
Image - (From left) Dale Edward Washington, Attorney of Vietnamese Dong Nam Pharma; Le Thi Giau, Chairwoman of Vietnamese Dong Nam Pharma; Hyeon-su Shin, Chairman of NTL Medical Institute; and Tae-hee Kim, CEO of NTL Healthcare.
The NTL Group (Chairman Hyeon-su Shin, CEO Tae-hee Kim) has laid the groundwork for entering the Vietnamese market.
NTL Group announced on the 8th that it has signed a memorandum of understanding (MOU) with Dong Nam Pharma (Chairwoman LE THI GIAU) for 'medical cooperation between the two sides for Vietnamese women's health promotion.'
On the 3rd, the signing ceremony was held at the headquarters of NTL Healthcare Co., Ltd. in Seongnam, Gyeonggi Province, attended by Hyeon-su Shin (Chairman of the NTL Medical Institute), Tae-hee Kim (CEO of NTL Healthcare), Le Thi Giau (Chairwoman of Dong Nam Pharma), and Dale Edward Washington (Attorney).
The agreement is aimed at improving the cervical cancer screening rate across Vietnam and promoting medical cooperation for the health promotion of Vietnamese women by supplying CerviCARE® AI, an economic and high-accuracy artificial intelligence (AI) screening system for cervical cancer, to Vietnam.
CerviCARE® AI is an AI screening system that can diagnose cervical cancer test results on site within 5 seconds (1). Based on big data accumulated by NTL for 27 years, it shows a high sensitivity. In December of last year, it was approved for a Class 3 AI software for gynecologic medical treatment from the Ministry of Food and Drug Safety.
NTL plans to supply the CerviCARE® AI system to all of Vietnam through Dong Nam Pharma. Following the management philosophy of Chairwoman Le Thi Giau, Dong Nam Pharma plans to launch a free AI screening program for cervical cancer targeting underprivileged women who have difficulty receiving medical services in 10 major cities out of 63 cities in Vietnam. It is also working on a long-term plan to apply the system to over 40,000 clinics and public health centers. In addition, academic research and seminars are planned to be held in Vietnam.
Hyeon-su Shin, Chairman of NTL Medical Institute, stated, "According to the WHO, the cervical cancer screening rate in Vietnam is only one-third that of Korea. It is the biggest cause of the high mortality rate of cervical cancer, and through this agreement, NTL will also provide fully support to improve the medical environment in Vietnam."
NTL received medical device approval from the Thailand Food and Drug Administration (TFDA) in April to expand into overseas markets, and is currently in the process of approval from the Brazilian Health Regulatory Agency (ANVISA) for registration.
Tae-hee Kim, CEO of NTL Healthcare, said, "CerviCARE® AI is a system that allows women to receive safe and convenient cervical cancer screening, regardless of borders and regions, even in areas where medical infrastructure is underdeveloped. Starting with Vietnam, we plan to expand the supply of CerviCARE® AI services to Southeast Asian countries such as Laos, Cambodia, Myanmar, and Indonesia."
Meanwhile, NTL is a company that introduced cervical magnification imaging and reading system in Korea in 1996, and its cervical cancer remote diagnosis system, developed with proprietary technology, has been verified in Korea and is currently expanding to various countries around the world.
Ref: 1) Test Report, Standard Bank, 2023
